The efficacy of this autophagic inhibitor has also been investigated, in a phase I/II clinical trial, in combination with binimetinib (MEK inhibitor), ulixertinib (ERK inhibitor) and gemcitabine, in pancreatic cancer and gastrointestinal adenocarcinomas [145,146]. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.